The rash on this 4-week-old girl had appeared 5 days earlier on her face as thickened scales on an erythematous base and subsequently spread to the scalp, shoulder, chest, abdomen, and extremities. A few bullae were noted on the neck and hands. Initial treatment with cephalexin failed to control the rash, and the infant was admitted to the hospital for further evaluation.
The rash on this 4-week-old girl had appeared 5 days earlier on her face as thickened scales on an erythematous base and subsequently spread to the scalp, shoulder, chest, abdomen, and extremities. A few bullae were noted on the neck and hands. Initial treatment with cephalexin failed to control the rash, and the infant was admitted to the hospital for further evaluation.
The white blood cell count was 14,400/μL (normal range, 5000 to 19,500/μL), with 11% eosinophils. Culture taken from a ruptured bulla grew Staphylococcus sciuri and Enterobacter asburiae. Several antibiotics were tried; S sciuri was resistant to oxacillin and penicillin G, and E asburiae was resistant to amoxicillin and ampicillin. Both organisms were sensitive to gentamicin, ciprofloxacin, and levofloxacin. The infant was treated with gentamicin and was switched to soy-based formula after IgG antibody test results for cow's milk allergen were found to be positive. By day 3, the infant had improved remarkably and was discharged.
The skin of patients with atopic dermatitis may become infected with opportunistic bacteria that prolong healing and may cause serious scarring and morbidities. These infections have been managed empirically, using therapies active against the most common causative organisms-S aureus and methicillin-resistant S aureus.1 However, clinicians who focus only on such common culprits may miss true diagnoses.
S sciuri is an important antibiotic-resistant organism to consider in this setting. It is associated with wound infection, peritonitis, urinary tract infection, pelvic inflammatory disease, splenic abscess, endophthalmitis, endocarditis, and septic shock.2-4 Resistance to macrolides, lincosamides, streptogramins, linezolid, and aminoglycosides has been reported.3,4E asburiae is a gramnegative rod that has been isolated from various human sources, such as urine, the respiratory tract, wounds, and blood. It has been linked to cases of communityacquired pneumonia.5
REFERENCES:
1.
Scheinfeld N. Superinfection of eczema with multiple
Acinetobacter
species.
Acta Derm Venereol
. 2003;83:143.
2.
Chen S, Wang Y, Chen F, et al. A highly pathogenic strain of
Staphylococcus sciuri
caused fatal exudative epidermitis in piglets.
PloS One
. 2007;2:e147.
3.
Stepanovic S, Martel A, Dakic I, et al. Resistance to macrolides, lincosamides, streptogramins, and linezolid among members of the
Staphylococcus sciuri
group.
Microb Drug Resist
. 2006;12:115-120.
4.
Hauschild T, Vukovic D, Dakic I, et al. Aminoglycoside resistance in members of the
Staphylococcus sciuri
group.
Microb Drug Resist
. 2007;13:77-84.
5.
Stewart JM, Quirk JR. Community-acquired pneumonia caused by
Enterobacter asburiae
.
Am J Med
. 2001;111:82-83.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.